Compare Organon & Co. Common Stock (OGN) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Suncor Energy Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Suncor Energy Inc. trades at $75.96 (market cap $87.48B). The key difference: Suncor Energy Inc. is far larger — about 24.2× Organon & Co. Common Stock's market cap, and Suncor Energy Inc. pays the higher dividend (2.26%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Suncor Energy Inc. for 57 Days on average.
| OGN | SU | |
|---|---|---|
Market Cap | $3.62B | $87.48B |
Volume | 2,892,999 | 3,692,639 |
Sector | Health | Energy |
52-Week High | $13.81 | $75.89 |
52-Week Low | $5.70 | $38.17 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $11.04B | $94.00B |
Dividend Yield | 0.58% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Suncor Energy (SU) trades at $75.89, up 3.24% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 14.32, net income margin of 14.7%, and consistent cash flow generation. Recent news highlights strategic asset divestitures and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings.
Outlook remains favorable given SU's integrated oil sands operations and aggressive shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges, but the company's strong balance sheet and improving debt metrics provide stability. Current valuation appears reasonable relative to earnings potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
